Company news
Unicycive Therapeutics, Inc. news in 2022
Unicycive Therapeutics, Inc.'s news releases, calls and decks from 2022, newest first.
Unicycive Announces Termination of “At-The-Market” Offering of Shares of Common Stock
December 28, 2022
Unicycive Achieves Primary Endpoint in Pivotal Bioequivalence Study of Renazorb
December 27, 2022
Unicycive Issued Notice of Acceptance to Initiate Phase 1 Study of UNI-494 Following Review of Clinical Trial Application by the Medicines and Healthcare Products Regulatory Agency in the United Kingdom
December 21, 2022
Unicycive Reports Key Findings of UNI-494 Efficacy in Preclinical Animal Model of Geographic Atrophy
November 20, 2022
Unicycive Announces Third Quarter Financial Results and Provides Business Update
November 13, 2022
Unicycive Completes Enrollment of Pivotal Bioequivalence Study for RENAZORB™ (lanthanum dioxycarbonate), an Investigational Treatment for Hyperphosphatemia in Chronic Kidney Disease (CKD) Patients on Dialysis
November 9, 2022
Unicycive Reports Key Findings of UNI-494 Efficacy in Preclinical Animal Model of Acute Kidney Injury (AKI)
September 6, 2022
Unicycive Announces Multiple Abstracts Selected for Presentation at American Society of Nephrology’s Kidney Week 2022
August 23, 2022
Unicycive Announces Second Quarter Financial Results and Provides Business Update
August 14, 2022
Unicycive Announces Exclusive License and Development Agreement with Lee’s Pharmaceutical Holdings Limited for Renazorb in China and Certain Other Asian Markets
July 17, 2022
Unicycive Initiates Pivotal Clinical Bioequivalence Study of Renazorb to Treat Hyperphosphatemia
June 1, 2022
Unicycive Announces First Quarter Financial Results and Provides Business Update
May 11, 2022
Unicycive Announces Key Opinion Leader Event Highlighting Novel Treatments in Kidney Diseases
April 13, 2022
Unicycive Announces Full Year 2021 Financial Results and Provides Business Update
March 30, 2022
Unicycive To Ring the Nasdaq Closing Bell on March 29, 2022
March 22, 2022
Unicycive Announces Renazorb Pre-clinical and Clinical Data Selected for Presentation at National Kidney Foundation Spring Clinical Meeting
February 1, 2022
Decks in 2022
- Corporate Update (December 2022)
Corporate update · 12 slides · Dec 28, 2022